In‐111 CYT‐103 monoclonal antibody imaging in patients with suspected recurrent colorectal cancer

Recurrent colorectal cancer is seen in as many as 40% of patients after curative resection. In view of the limitations of endoscopic and cross‐sectional imaging, external immunoscintigraphy has been added to the follow‐up regimen of patients at high‐risk of recurrent disease. The authors investigated the utility of immunoscintigraphy with Indium‐111 (In‐111) CYT‐103 (site specifically labeled conjugate of monoclonal antibody B72.3) in 19 patients with suspected recurrences after previous curative resection of colorectal carcinoma. Local or regional recurrences (4 patients) and liver metastasis (6 patients) were indicated by physical examination and computed tomography (CT), whereas nine patients had occult disease with increasing serum carcinoembryonic antigen (CEA) levels and negative conventional workups. Serum CEA levels were elevated (mean, 22 ng/ml) in all patients. Approximately 4.3 mCi In‐111 labeled to 1.0 mg CYT‐103 was administered intravenously to each patient. Planar and single photon emission computed tomography (SPECT) imaging were performed 2–5 days after infusion. The final diagnosis of recurrence or metastasis was established in 18 patients by second‐look surgery or biopsy. One patient died before exploration. Tumor was identified at the following locations: pelvis (12 patients), abdominal wall (2 patients), retroperitoneum (1 patient), liver (5 patients), and omentum (2 patients). Superiority of monoclonal antibody (MoAb) scan is noted in the detection of pelvic and intraabdominal recurrences (100%) versus CT scan (43%). Liver metastases were identified with equal facility by both modalities. In‐111 CYT‐103 scan findings influenced the management of 10 (55%) of 18 patients. Surgery was avoided in one patient with disseminated metastases detected by the scan. Correct identification of occult local recurrences was made in six patients. An isolated liver metastasis was confirmed in one patient with equivocal CT scan. Finally, additional intraabdominal lesions were detected in two patients. These results suggest an important and beneficial role for In‐111 CYT‐103 MoAb imaging in patients with suspected recurrent colorectal carcinomas, particularly in patients in whom cross‐sectional imaging is negative; such imaging may prevent patients from undergoing unnecessary surgical exploration.

[1]  R. Maguire,et al.  In-111-labeled monoclonal antibody immunoscintigraphy in colorectal carcinoma: safety, sensitivity, and preliminary clinical results. , 1990, Radiology.

[2]  A. Chang,et al.  Differences in biodistribution of indium-111-and iodine-131-labeled B72.3 monoclonal antibodies in patients with colorectal cancer. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  D. E. Simpson,et al.  Radioimmunoscintigraphy of colon cancer with iodine-131-labeled B72.3 monoclonal antibody. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[4]  E. Martin,et al.  Multiple reoperations in recurrent colorectal carcinoma. An analysis of morbidity, mortality, and survival , 1988, Cancer.

[5]  J. Schlom,et al.  Peritoneal carcinomatosis: imaging with intraperitoneal injection of I-131-labeled B72.3 monoclonal antibody. , 1988, Radiology.

[6]  H. Abdel-Nabi,et al.  Colorectal tumors: scintigraphy with In-111 anti-CEA monoclonal antibody and correlation with surgical, histopathologic, and immunohistochemical findings. , 1988, Radiology.

[7]  P. Sugarbaker,et al.  A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. , 1987, Surgery.

[8]  R. Halvorsen,et al.  Computed tomographic staging of gastrointestinal malignancies. Part II. The small bowel, colon, and rectum. , 1987, Investigative radiology.

[9]  A. Thor,et al.  Tumor-associated glycoprotein (TAG-72) in ovarian carcinomas defined by monoclonal antibody B72.3. , 1986, Journal of the National Cancer Institute.

[10]  A. Thor,et al.  Distribution of oncofetal antigen tumor-associated glycoprotein-72 defined by monoclonal antibody B72.3. , 1986, Cancer research.

[11]  V. L. Alvarez,et al.  Site-specific covalent modification of monoclonal antibodies: in vitro and in vivo evaluations. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Daly,et al.  Hepatic resection for metastases of the colon and rectum. , 1986, Surgery, gynecology & obstetrics.

[13]  P. Freeny,et al.  Colorectal carcinoma evaluation with CT: preoperative staging and detection of postoperative recurrence. , 1986, Radiology.

[14]  L. Carey,et al.  CEA‐Directed Second‐look Surgery in the Asymptomatic Patient after Primary Resection of Colorectal Carcinoma , 1985, Annals of surgery.

[15]  A. Cruz,et al.  Results of a 400‐patient carcinoembryonic antigen second‐look colorectal cancer study , 1985, Cancer.

[16]  B. Cady,et al.  Major Hepatic Resection for Metachronous Metastases from Colon Cancer , 1985, Annals of surgery.

[17]  D. Ilstrup,et al.  Resection of hepatic metastases from colorectal cancer. , 1984, Archives of surgery.

[18]  M. Korobkin,et al.  The pelvis after surgery for rectal carcinoma: serial CT observations with emphasis on nonneoplastic features. , 1983, AJR. American journal of roentgenology.

[19]  F. E. White,et al.  The appearances on computed tomography after abdominoperineal resection for carcinoma of the rectum: a comparison between the normal appearances and those of recurrence. , 1983, The British journal of radiology.

[20]  T. Starzl,et al.  Experience with 150 Liver Resections , 1983, Annals of surgery.

[21]  R. Mariani-Costantini,et al.  A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor‐associated antigen in human mammary carcinoma cell populations , 1982, International journal of cancer.

[22]  R. Levitt,et al.  CT appearance of the pelvis after abdomino-perineal resection for rectal carcinoma. , 1981, Radiology.

[23]  P. Hand,et al.  A spectrum of monoclonal antibodies reactive with human mammary tumor cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[24]  R. Wilson,et al.  Patterns of recurrence following curative resection of adenocarcinoma of the colon and rectum , 1980, Cancer.

[25]  R. Fischer,et al.  Slope analysis of the postoperative CEA time course and its possible application as an aid in diagnosis of disease progression in gastrointestinal cancer. , 1978, American journal of surgery.

[26]  E. Martin,et al.  The use of serial carcinoembryonic antigen determinations to predict recurrence of carcinoma of the colon and the time for a second-look operation. , 1978, Surgery, gynecology & obstetrics.

[27]  R. Million,et al.  Patterns of recurrence following surgery alone for adenocarcinoma of the colon and rectum , 1976, Cancer.

[28]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[29]  J. Minton,et al.  CEA as an adjunct in the diagnosis and prognosis of colorectal carcinoma. , 1975, Review of surgery.

[30]  R. Taylor,et al.  CARCINOEMBRYONIC ANTIGEN , 1974 .

[31]  J. Oldhoff,et al.  [Surgical treatment of pulmonary metastases]. , 1969, Nederlands tijdschrift voor geneeskunde.

[32]  R. Fitzgibbons,et al.  Patterns of recurrence after curative resection of carcinoma of the colon and rectum. , 1992, Surgery, gynecology & obstetrics.

[33]  H. Abdel-Nabi,et al.  Safety and role of repeated administrations of Indium-111-labeled anti-carcinoembryonic antigen monoclonal antibody ZCE 025 in the postoperative follow-up of colorectal carcinoma patients. , 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.